ROSEN, THE FIRST FILING FIRM, Encourages Netcapital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action...

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

The Inner Circle acknowledges Dr. Reuben Azad as a Pinnacle Lifetime Member Inner Circle of Excellence

TRexBio Announces Pricing of Initial Public Offering

Crypto News: AlphaPepe Binance Listing Update Drives Presale Surge as Bitcoin Price Prediction Eyes $200K

'NBA Cares x Sands Cares Community Impact Week 2026' Celebrates Tip-Off

INFiLED Launches NX Series for Stage Productions

ROSEN, LEADING INVESTOR COUNSEL, Encourages Duolingo, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action ...

Notice of Data Security Incident

iSpring Launches Its Redesigned Website Alongside a New Membership Program, Bringing More Convenience and Rewards to Customers

Nurse Approved Certification and the National Nurse Practitioner Entrepreneur Network Launch Strategic Referral and Co-Curated Event...

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -...

SUMMIT ROYALTIES ANNOUNCES MARKETING AND INVESTOR RELATIONS AGREEMENTS

Bits In Glass achieves Select Partner Status in the Claude Partner Network Services Track

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages York Space Systems Inc. Investors to Secure Counsel Before Important Deadline in Securities...

MedStar Health Introduces New Airbus H145 D3 Helicopter to Expand Critical Care Capabilities Across the Region

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in...

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in...

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease